Nuclera is a Bioprinter company that enables life science researchers to accelerate breakthrough improvements in human health through easy access of biomolecules.
My fellow co-founders -- Jiahao, Gordon, and Radu -- and I founded Nuclera in 2013 during the first year of our PhDs at the University of Cambridge. Being scientists at heart, we believe that inaccessibility is the key bottleneck in biology. It was certainly the number one obstacle to finishing our dissertations.
Since then, we’ve made it our mission to solve biological inaccessibility. This drive feeds into our collective vision to make biology accessible to everyone through desktop bioprinting. We do this by providing tools designed by scientists for scientists.
Nuclera is now the leading pioneer in making biology accessible by combining its eProtein™ and eDNA™ bio-inks with eDrop™ digital microfluidics. The combination of these technologies into a desktop bioprinter creates an unprecedented one-stop shop ecosystem that enables our customers to streamline and program biology. Get in touch if you want to make biology accessible with us or simply have a question.
Co-founder & CEO
Strong engineering foundation
Proprietary hardware - software integration in the bioprinter platform
Exceptional R&D team
45+ patent families powering the world's first benchtop bioprinter
Rapid advancement in therapeutic drug development and Synthetic Biology
Headquartered in Cambridge UK, Nuclera in 2021 expanded to Billerica, Massachusetts, USA. Our internationally diverse team comprises scientists driving our applications workflows, engineers refining our eDrop technology and building our desktop bioprinting platform, and software developers creating analytical algorithms and frictionless interfaces.
Prof. George Church
Our mission is simple: provide high-quality, soluble and active proteins at your benchtop.Sign Up